Ponaxen 15 (Ponatinib) 15 mg Tablets

Indicated for the treatment of adult patients with:

• 🔹 Chronic Myeloid Leukemia (CML): in chronic, accelerated, or blast phase in patients resistant or intolerant to other tyrosine kinase inhibitors.
• 🔹 Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL): when prior therapy has failed or is not appropriate.
• 🔹 T315I mutation: in patients with confirmed BCR-ABL T315I mutation.

Packaging: 15 mg tablets.

⚠️ ADMINISTRATION PROTOCOL:

• Dose: Determined individually by the treating physician. The 15 mg tablet is often used for reduced maintenance dosing or stepwise dose adjustment.
• Food Intake: Can be taken with or without food.
• Administration: Swallow the tablet whole with water.
• Monitoring: Regular monitoring of blood counts, liver function, lipase, blood pressure, and cardiovascular status is required.
• Note: Use only under the supervision of a hematologist or oncologist.

• Hypersensitivity to Ponatinib or any excipient of the product.
• Pregnancy and breastfeeding.
• Use in children under 18 years of age is not established.
• Use with caution in patients with hypertension, ischemic heart disease, thrombosis, hepatic impairment, or pancreatitis.